Inimmune

Innovation is driven by people.

At Inimmune, our team brings together deep expertise in immunology, clinical development, and translational science – all focused on advancing new solutions for patients.

Learn more about us: https://inimmune.com/

Inimmune is proud that our very own scientists have been published again.

Characterization of a transmembrane-activating STING agonist using genetically humanized mice Mizuno et al. describe the synthesis of a human-selective STING agonist, INI3069, that activates conventional TBK1-mediated cellular processes such as IRF3 phosphorylation and ISG expression while blocking TBK1-independent phenotypes including TFEB activation, autophagy, and Golgi trafficking. Using...

is around the corner!

Inimmune will be participating in this year’s meeting, where our CEO, David Burkhart, Ph.D., is scheduled to present on our approach to advancing disease-modifying and progress from our INI-2004 program.

📍 June 24, 4:15-4:30 p.m. PT

Learn more: https://convention.bio.org/speakers/david-burkhart

Innovation Organization

May is , a month dedicated to helping patients and families educate their communities and advocate for safety.

Food allergies may be unseen, but they should never be unnoticed. At Inimmune, we’re advancing our allergy program with the needs of millions of people worldwide living with in mind.

Our CEO, David Burkhart, Ph.D., will present at the Food Allergy Fund Summit taking place April 29, 2026, in NYC.

Dr. Burkhart will join leaders advancing new approaches to treatment and prevention to discuss translating science into solutions for patients with food allergies.

We look forward to joining these critical conversations shaping the future of research and innovation.

Check out the agenda here: https://foodallergyfund.org/summit2026

What does it take to develop a disease-modifying therapy for allergic rhinitis?

In a recent interview with Leader’s Proch, our CEO Burkhart shares how Inimmune is advancing INI-2004, a novel intranasal designed to reprogram the immune system and deliver durable responses for patients.

The discussion also explores the nuances of clinical trials, from seasonal timing to the role of controlled chamber studies in improving signal detection.

Read more: https://www.clinicalleader.com/doc/considerations-for-allergic-rhinitis-trials-are-nothing-to-sneeze-at-0001

Considerations For Allergic Rhinitis Trials Are Nothing To Sneeze At Inimmune CEO David Burkhart explains how a GSK layoff led to the formation of a new company focused on treating allergic rhinitis. Here, he shares success from the companys approach to site selection, trial design, and timing.

INIMMUNE IS ON THE MOVE AT THE WVC

We’re excited to share some big updates—highlighted by a special co-presentation from our own Dr. Juhienah Khalaf alongside Dr. Peter Tygesen, Business Development Director at SPI Pharma (our valued partner):
🗓 March 30
📍 Room 209AB
🕛 12:20 PM EST
“Innovative Adjuvants for Global Health.”
Join us at WVC in Washington, DC for the presentation and visit us at booth #452 to explore our cutting-edge adjuvant system pipeline and see how we’re helping shape the future of global health. 💉🔬